Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 79,000 shares, a growth of 101.5% from the March 31st total of 39,200 shares. Currently, 2.2% of the company’s stock are sold short. Based on an average daily trading volume, of 206,900 shares, the short-interest ratio is presently 0.4 days.

Galmed Pharmaceuticals Price Performance

Galmed Pharmaceuticals stock remained flat at $0.39 during mid-day trading on Friday. 27,223 shares of the company were exchanged, compared to its average volume of 260,258. Galmed Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $7.80. The company’s 50 day moving average price is $0.36 and its 200-day moving average price is $0.38. The firm has a market cap of $1.98 million, a P/E ratio of -0.12 and a beta of 0.87.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its earnings results on Thursday, April 4th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on Galmed Pharmaceuticals in a research note on Wednesday. They set a “sell” rating for the company.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.